Dilated cardiomyopathy

Precision Targeting of the Sarcomere: Danicamtiv Shows Genotype-Specific Efficacy in Dilated Cardiomyopathy

By MedXY 01/16/2026

A Phase 2 trial demonstrates that danicamtiv, a novel cardiac myosin agonist, significantly improves left ventricular function in patients with genetic forms of dilated cardiomyopathy, particularly those with MYH7 and TTN variants, signaling a shift toward precision cardiology.

Cardiology news

Beyond the Mutation: Uncovering the Triggers of Disease Onset in Titin-Related Dilated Cardiomyopathy

By MedXY 01/03/2026

An international multicenter study reveals that while Titin-truncating variants significantly increase cardiomyopathy risk, disease onset is heavily influenced by male sex, co-morbidities, and atrial fibrillation, while early prophylactic therapy may offer substantial protection.

Cardiology news

Beyond Arrhythmia: High-Risk Genotypes in Dilated Cardiomyopathy Predict Progression to Advanced Heart Failure

By MedXY 01/03/2026

A landmark Spanish study reveals that patients with 'arrhythmic' genotypes in dilated cardiomyopathy face a significantly higher risk of advanced heart failure events, including heart transplantation and VAD implantation, necessitating a paradigm shift in clinical management.

Cardiology news

Caring for Families After a Dilated Cardiomyopathy Diagnosis: Practical Guidance from the 2025 Clinical Consensus

By MedXY 11/29/2025

A focused guide to modern genetic and clinical screening of relatives after a dilated cardiomyopathy diagnosis, summarizing the 2025 clinical consensus and practical steps for clinicians and families.

Cardiology Specialties

Sex-Specific Genetic Insights into Dilated Cardiomyopathy: The Key Role of Desmoplakin Variants

By MedXY 08/22/2025

Desmoplakin gene variants confer a higher risk and penetrance of dilated cardiomyopathy in females, contrasting with male-predominant risks from other genes like TTN. This discovery underscores sex-specific mechanisms in DCM susceptibility and prognosis.